You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CML in chronic phase

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metabolic Alternation and Clinicohematological Characteristic in

Not yet recruiting
  • CML, Chronic Phase
  • Tyrosine kinase inhibitor
  • (no location specified)
Nov 6, 2023

CML, Chronic Phase, CML, Accelerated Phase Trial in Wuhan (HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion))

Recruiting
  • CML, Chronic Phase
  • CML, Accelerated Phase
  • HS-10382(Part 1: Dose escalation)
  • HS-10382(Part 2: Dose expansion)
  • Wuhan, Hubei, China
    Union Hospital affiliated to Tongji Medical College of Huazhong
Jan 12, 2023

Among CP-CML Participants Initiating Dasatinib inReal Life

Completed
  • Chronic Myeloid Leukemia
  • Non-Interventional
  • Paris, France
    Local Institution
Jun 17, 2022

CML, Chronic Phase Trial in Harbin (Flumatinib, Imatinib)

Not yet recruiting
  • CML, Chronic Phase
  • Harbin, Heilongjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
May 5, 2022

Chronic Myeloid Leukemia Trial (Asciminib)

Available
  • Chronic Myeloid Leukemia
  • (no location specified)
Jan 17, 2023

Ponatinib in CML Patients in Chronic Phase

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • Therapeutic drug monitoring
  • Molecular Response
  • Cagliari, Italy
  • +4 more
Nov 3, 2023

CML, Chronic Phase Trial in Harbin (Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg))

Recruiting
  • CML, Chronic Phase
  • Flumatinib mesylate tablets (400mg)
  • Flumatinib mesylate tablets (600mg)
  • Harbin, Hei Longjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
Apr 28, 2022

CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

Recruiting
  • CML
  • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
  • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
    FUNDALEU
Jun 29, 2023

CML (Chronic Myelogenous Leukemia Trial (KDS-1001)

Not yet recruiting
  • CML (Chronic Myelogenous Leukemia
  • (no location specified)
Jul 27, 2022

Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid Trial in Augusta, Milwaukee (Asciminib, Ascimininb +

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • +3 more
  • Augusta, Georgia
  • +1 more
Jul 14, 2022

Myeloproliferative Tumor, Chronic Phase Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia Trial in San Francisco (Online

Recruiting
  • Myeloproliferative Neoplasm
  • +2 more
  • Online Mindfulness Meditation
  • Internet-Based Webinars
  • San Francisco, California
    University of California San Francisco
Aug 9, 2022

Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukaemia Transformation, Chronic Myeloid Leukemia -

Recruiting
  • Chronic Myeloid Leukemia in Myeloid Blast Crisis
  • +3 more
  • based decitabine and olverembatinib（HQP1351)chemotherapy
  • Guanzhou, China
    Department of Hematology, Nanfang Hospital, Southern Medical Uni
Dec 6, 2022

Chronic Myelogenous Leukemia Trial in Beijing (TGRX-678)

Recruiting
  • Chronic Myelogenous Leukemia
  • Beijing, Beijing, China
    Peking University People's Hospital
Jun 27, 2022

Chronic Phase Chronic Myelogenous Leukemia Trial in Detroit, Milwaukee (Asciminib, Imatinib)

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • Detroit, Michigan
  • +1 more
May 3, 2022

Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory Trial in Worldwide (Radotinib HCl)

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • +3 more
  • Radotinib HCl
  • Uijeongbu-si, Gyeonggi-do, Korea, Republic of
  • +17 more
Jan 3, 2022

Chronic Myeloid Leukemia in Chronic Phase Trial in Shenzhen (Flumatinib, Dasatinib)

Recruiting
  • Chronic Myeloid Leukemia in Chronic Phase
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022

Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors Trial in Shenzhen (olverembatinib)

Recruiting
  • Olverembatinib
  • +2 more
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022

Flumatinib, Chronic Myeloid Leukemia, Chronic Phase, Imatinib Trial in Shenzhen (Flumatinib)

Recruiting
  • Flumatinib
  • +2 more
  • Shenzhen, Guangdong, China
    The Second People's Hospital of Shenzhen
Mar 15, 2022

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Trial (Asciminib, Nilotinib)

Not yet recruiting
  • Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
  • (no location specified)
Jul 11, 2022

Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission Trial (Asciminib, Imatinib)

Not yet recruiting
  • Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
  • (no location specified)
Jun 7, 2022

Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Suzhou (Azacitidine, Venetoclax,

Recruiting
  • Philadelphia Chromosome
  • +4 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jun 23, 2022

Leukemia, Chronic Myelogenous Trial in China (asciminib, best available treatment)

Recruiting
  • Leukemia, Chronic Myelogenous
  • Chongqing City, Chongqing, China
  • +23 more
Jan 18, 2023

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Jun 24, 2022

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase

Recruiting
  • CML, Chronic Phase; TKI
  • Flumatinib Mesylate
  • Nilotinib Pill
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
Feb 1, 2021

Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022